August 26, 2025 — Circurna, a biotechnology company advancing its ciRNA™ circular RNA platform, and GATC Health, a tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, announced an agreement to accelerate discovery and optimization for Circurna’s ciRNA™ circular RNA therapeutics by applying GATC’s AI platform. The collaboration aims to enhance the design, delivery, and targeting of Circurna’s next-generation RNA therapeutics.
Under the agreement, GATC will receive a combination of cash and equity compensation, along with milestone-based incentives. Circurna will leverage the results from GATC’s AI platform to optimize key components of its ciRNA™ therapeutics, including LNP designs for thermostability, targeting ligands for delivery to specific cells and tissues, and improved payload candidates.
Dr. Mariano García-Blanco, Co-Founder and Scientific Advisor of Circurna, stated that GATC’s AI discovery platform was selected as the best assurance of getting its ciRNA™ platform on the right path with speed and precision. Jayson Uffens, Co-founder and Chief Technology Officer of GATC Health, added that Circurna’s choice of GATC will accelerate their path to success in the RNA field.
Circurna is a pre-clinical stage biotechnology company developing next-generation therapeutics powered by its ciRNA™ platform. GATC Health is a technology-driven biopharmaceutical company revolutionizing drug discovery and development through its Multiomics Advanced Technology™ (MAT) platform.
Circurna Media Contact:
Madelyn De Los Santos
Putnam Insights LLC
Madelyn@putnaminsights.com
GATC Media Contact:
Mike Tattory
LifeSci Communications
Mtattory@lifescicomms.com
Source: Circurna
